Antiplatelet treatment is a potential therapeutic approach for sickle cell disease (SCD). Ticagrelor inhibits platelet aggregation and is approved for adults with acute coronary syndrome and following myocardial infarction. HESTIA1 (NCT02214121) was a 2-part, phase 2 dose-finding study generating ticagrelor exposure, platelet inhibition, and safety data in children with SCD (3-17 years). In part A (n = 45), patients received 2 ticagrelor single doses, 0.125-2.25 mg/kg (washout ≥7 days), then 7 days of twice-daily (bid) dosing with 0.125, 0.563, or 0.75 mg/kg. In the 4-week blinded Part B extension (optional), patients received ticagrelor (0.125, 0.563, or 0.75 mg/kg bid; n = 16) or placebo (n = 7). Platelet reactivity decreased from baseline to 2 hours postdosing, and returned to near baseline after 6 hours postdosing. Dose-dependent platelet inhibition was seen with ticagrelor; mean relative P2Y 12 reaction unit inhibition 2 hours after a single dose ranged from 6% (0.125 mg/kg) to 73% (2.25 mg/kg). Ticagrelor plasma exposure increased approximately dose proportionally. No patients experienced a hemorrhagic event during treatment. No differences were seen between groups in pain ratings and analgesic use during Part B. Ticagrelor was well tolerated with no safety concerns, no discontinuations due to adverse events (AEs), and reported AEs were mainly due to SCD. In conclusion, a dose-exposure-response relationship for ticagrelor was demonstrated in children with SCD for the first time. These data are important for future pediatric studies of the efficacy and safety of ticagrelor in SCD.
| INTRODUCTION
Current understanding of sickle cell disease (SCD) includes pathophysiology beyond the red blood cell, for example, inflammation, oxidant stress, vasoregulation, endothelial dysfunction, and thrombosis. [1] [2] [3] [4] [5] Platelet activation is at the cross-roads of most of these pathophysiologic pathways, both acute and chronic. In SCD, during the non-crisis "steady state" platelets are activated, and during painful episodes, platelets are further activated. 6 This process promotes adherence of sickle cells to vessel walls thereby contributing to vaso-occlusion. Furthermore, platelets have a pivotal role in adhesion of neutrophils during vaso-occlusive crises (VOCs). 7 Based on these findings, inhibiting platelet activation maybe a potential therapeutic option to reduce VOC risk in SCD. However, a recent, phase 3 trial (DOVE) with the antiplatelet agent prasugrel in 341 children and adolescents with SCD, reported a small numerical reduction of VOC events with prasugrel (328 events, 2.30 events/person-year) vs placebo (408 events, 2.77 events/person-year) and no increased bleeding risk with prasugrel. 8 In addition, the reduction in VOC rate did not reach statistical significance in the DOVE trial. 8 A potential limitation of the DOVE trial was that the observed level of platelet inhibition (P2Y 12 reaction units
[PRU]) was only~20% from baseline. 9 Thus, it is of interest to assess the potential clinical consequences of a higher level of platelet inhibition in patients with SCD.
The direct-acting antiplatelet agent ticagrelor binds reversibly to the P2Y 12 receptor and inhibits adenosine diphosphate-induced platelet aggregation. [10] [11] [12] Ticagrelor also reduces cellular uptake of adenosine via inhibition of nucleoside transporter 1; 12-14 this effect may have vasodilatory or anti-inflammatory effects in ischemic tissues during impending or ongoing VOC. Based on the results of 2 phase 3 trials in adults with coronary artery disease (PLATO study, PEGASUS-TIMI 54 study), 15, 16 ticagrelor with low-dose aspirin (75-100 mg/d) is currently indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in adult patients with acute coronary syndrome or a history of myocardial infarction. 17 In adults, the pharmacokinetics (PKs) and pharmacodynamics (PDs) of ticagrelor and its active metabolite (AR-C124910XX) have been extensively evaluated. [18] [19] [20] [21] Harmonization/Good Clinical Practice Guidelines, and followed applicable regulatory requirements and the AstraZeneca policy on bioethics.
| Study design and treatments
HESTIA1 was a phase 2 multicenter study consisting of 2 parts (Supporting information Figure S1 ). In both parts, ticagrelor (or matching placebo) was administered as an oral suspension. All patients were followed up 30-35 days after the last dose of study drug.
| Platelet inhibition and plasma exposure assessments
In part A, 4 mL blood samples for PRU assessments were collected predose and 2 hours postdosing and at 6 hours (patients >21 kg), after single ticagrelor doses. At the end of 7 days of repeated dosing, PRU samples were collected predose and 2 hours postdose. In the optional part B, sampling for PRU assessments could be collected after 4 weeks pre and postdose. PRU assessments were measured in each study center following blood collection, using the VerifyNow system that has been validated for direct clinical use and is a commercially avail- Ticagrelor and the active metabolite were quantified in plasma using a fully validated liquid chromatography tandem mass spectrometry method. 22 Ranges of the calibration curves were 1-2000 ng/mL (ticagrelor) and 2.5-1000 ng/mL (AR-C124910XX) with a 100 μL sample volume. 
| Safety

| Exploratory efficacy analyses and palatability assessments
In both parts of the study, patients ≥4-years old completed an electronic diary on a handheld device (with the help of a parent/guardian as appropriate) daily to record pain (including intensity), analgesic use (including opioids), and days absent from school/work (ages ≥6 years only). From these diaries, the following efficacy variables were derived: days with pain, intensity of pain, days of analgesic use, days of opioid analgesic use, and days of absence from school or work.
Investigational product palatability was assessed qualitatively in a standardized way by a nurse at the study site based on observation of willingness to swallow the study drug and negative response behavior in children <6-years old, and was patient-reported using the Hedonic Faces Scale (5-point scale ranging from "dislike very much" to "like very much") in patients ≥6 years.
| Descriptive data analyses
No formal sample size calculation was performed. The sample size was selected to generate sufficient data for a population PK-PD modeling-and simulation-based dose selection in subsequent efficacy studies, whilst exposing a minimum number of pediatric patients to 
| Patient disposition and demographics
A total of 18 centers screened patients (see acknowledgments), and 17 sites randomized patients in the USA (6), UK (4), Kenya (2), Lebanon (2), South Africa (2), and Canada (1) between September 11, 2014 (first patient randomized) and February 27, 2017 (last patient completed the study).
In part A, 46 patients were randomized, 45 received at least 1 ticagrelor dose, and 39 patients completed this part (Supporting Information Figure S2 ). The discontinuation reasons were: patient decision (n = 2; 1 of these patients had insufficient venous access to obtain a predose blood sample and was not dosed; neither withdrawal was due to AEs); development of study-specific withdrawal criteria (ie, repeated low PRU values; n = 4). A total of 25 patients were randomized, 23 received the relevant study treatment, and 21 patients completed part B (Supporting Information Figure S2 ). The discontinuation reasons were: patient decision (n = 1; ticagrelor); development of study-specific withdrawal criteria (ie, repeated low PRU values; n = 2; ticagrelor); and lost to follow-up (n = 1; placebo).
Key demographic/baseline characteristics for patients dosed with ticagrelor in part A are shown in Table 1 . Mean patient age was 11.2 years, and most patients (77.8%) were Black or African American.
Twenty-four patients (53.3%) were female, and about two-thirds (66.7%) of patients had experienced a prior SCD complication (Supporting Information Table S1 ). Approximately 80% of patients were being treated with hydroxyurea.
Treatment compliance was high; median compliance with dosing was 100% in part A and 97.4% (ticagrelor) and 98.3% (placebo) in part B. In the 4-week long part B, patients took the study drug for a mean (SD) of 27.4 (6.4) and 29.4 (3.4) days in the ticagrelor and placebo groups, respectively.
| Platelet inhibition response
A clear dose-response relationship was seen, and the effect on both absolute and relative PRU is shown in Figure 1 . As expected, due to the reversible mode of action of ticagrelor, PRU values returned towards baseline levels with the decline in ticagrelor plasma exposure at 6-8 postdose (data not shown). In part A, PRUs measured prior to dosing were 
| Safety and tolerability
No deaths or AEs leading to discontinuation of the study drug or to patient withdrawal occurred during either part of the study. The Table 2 ). The most commonly reported AEs in part A were sickle cell anemia with crisis (ie, vaso-occlusive pain), abdominal pain, arthralgia, and pain in extremity (Table 2) . Similarly, these AEs were also the most common in part B in both the ticagrelor and placebo groups ( Table 2) . No patients experienced a hemorrhagic event during treatment, although 1 patient in the ticagrelor group in part B reported a mild spontaneous epistaxis on day 29 after the last ticagrelor dose during the follow-up period, which was considered to be a minor bleed.
Two patients in part A developed AEs that were considered to be treatment related as judged by the investigator: 1 patient had abdominal pain, and the other patient had headache and jaundice. No treatment-related AEs were reported in part B.
Most AEs were mild-to-moderate in intensity. Three patients in each part of the study had severe AEs as judged by the investigator, none of which were considered related to ticagrelor: sickle cell anemia with crisis (n = 2) and acute chest syndrome (n = 1) in part A, and sickle cell anemia with crisis (n = 2; ticagrelor group) and acute chest syndrome (n = 1; ticagrelor group) in part B.
There were no clinically meaningful differences across the groups in the physical examinations, vital signs, ECGs, or changes from baseline in laboratory parameters (hematology, clinical chemistry, and urinalysis).
| Exploratory efficacy analyses and palatability
During part A, 43 of 44 children ≥4-years old reported in the electronic diary. The mean (SD) proportion of self-reported days with pain was 25.1% (31.1). In part B, the mean (SD) proportion of self-reported days with pain was similar between ticagrelor (n = 14) and placebo (n = 8), that is, 27.0% (24.1) and 31.8% (23.7), respectively. There were no clinically relevant findings or differences between ticagrelor and placebo in any of the other exploratory efficacy variables assessed (data not shown).
Palatability was generally good. Children <6-years old swallowed the ticagrelor suspension without problem and did not exhibit any negative response behavior. For children ≥6 years, the number selfreporting "dislike very much", "dislike a little", "not sure", "like a little", and "like very much" was 1 (2.3%), 12 (27.9%), 10 (23.3%), 11 (25.6%), and 6 (14.0%), respectively.
| DISCUSSION
HESTIA1 is the first pediatric study to demonstrate the relationship between ticagrelor dose, exposure and inhibition of platelet 
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A similar platelet inhibition response in different age groups is consistent with the results of an in-vitro investigation comparing the anti-platelet potency of ticagrelor in children and adults. 24 In this in vitro assessment, ticagrelor (0.01-10 μmol/L) was added to plateletrich plasma from infants and children (0-2, 2-6 months, 6 months-2 years, 2-6, and 6-12 years) and adults (≥18 years), and platelet inhibition was evaluated. For all infant and child age groups, the potency of ticagrelor was comparable with that seen in adults. These findings suggest that at equivalent levels of drug exposure, children and adults would have a comparable antiplatelet response to ticagrelor, and that platelets in children do not react differently to ticagrelor, 24 which are supported by our current findings in pediatric patients with SCD.
HESTIA1 did include limited secondary/exploratory efficacy assessments. Due to the small number of patients analyzed for these efficacy variables and the fact that most patients randomized to ticagrelor received a dose providing only minor platelet inhibition, the ability to draw conclusions was limited with regard to clinical efficacy.
A further constraint of this analysis was the short study duration. A longer study with a larger group of patients would be required to evaluate the potential effects of ticagrelor on VOCs in SCD.
There is a clear physiological rationale for studying antiplatelet agents in SCD. Interactions between sickle cells, endothelial cells, and plasma constituents initiate and sustain vaso-occlusion. 2 Platelet activation is increased in SCD patients even in the basal state, and increases further during VOC. 6 Not only does platelet activation directly increase blood coagulability, it also potentiates or activates other clotting pathways that contribute to intravascular thrombosis and vasculopathy. 6 Thus, inhibition of platelet activation has potential as a therapeutic option in SCD, and may result in decreased incidence and severity of vaso-occlusion and modification of other disease manifestations related to microvascular occlusion. 8 at a modest platelet inhibition. 9 The present HESTIA1 study evaluated a broad range of platelet inhibition which was well tolerated with no safety concerns raised for the ticagrelor dose range evaluated. These findings, therefore, pave the way for future studies with ticagrelor to evaluate the efficacy and safety of a higher degree of platelet inhibition than in previous outcome studies in SCD with platelet inhibitors.
No safety concerns were raised in pediatric patients receiving single and multiple doses of ticagrelor in the present study, and ticagrelor had an acceptable tolerability profile in this age group. No bleeding events were seen during treatment with ticagrelor. Indeed, most of the reported AEs in HESTIA1 are consistent with common medical issues in children with SCD. [28] [29] [30] [31] However, the safety profile of ticagrelor in this population will need further investigation in subsequent studies to establish the efficacy-safety profile.
Our study is not without limitations. A small number of patients were randomized, although it is not appropriate to use large numbers of children at the early dose-ranging phase of clinical research.
The observed PRU values were variable, as seen in the baseline samples and following placebo treatment. The observed higher platelet inhibition with 0.563 mg/kg bid compared with 0.75 mg/kg bid ticagrelor may be attributed to the relatively small number of patients and the observed variability in the PRU assay. The study also had a short duration, and was not statistically powered to detect differences in clinical outcomes (ie, endpoints evaluated in the exploratory analyses reported herein) and safety vs placebo.
However, this study was conducted at multiple centers around the world and ticagrelor was evaluated on a background of hydroxyurea in most patients, capturing data from a population representative of the global SCD population.
In conclusion, HESTIA1 is the first study to assess the dose to ticagrelor and AR-C124910XX exposure, and dose to platelet inhibition response profile in children with SCD. The sensitivity to ticagrelor on platelet inhibition in these children appeared to be similar to that observed in healthy adults and adult patients with acute coronary syndrome/coronary artery disease. Overall, no safety concerns were raised from treating pediatric patients with a broad range of single and repeated doses of ticagrelor during the study. The potential of ticagrelor to impact SCD-related pain crises warrants further evaluation in this population, and a phase 3 study (HESTIA3) is planned. 32 
